Malignant melanoma stage III

17 trials 5 recruiting MedDRA PT
17 Registered trials
5 Recruiting
13 Unique sponsors
13 Unique IMPs
11 Commercial trials
Drug classes (ATC)
— ATC code not specified 8
L Oncology (ATC L) 9
Mechanism of action (INN-stem analysis)
Unknown / small molecule 7 substances
Checkpoint inhibitor (PD-1) 2 substances
Monoclonal antibody (immune) 1 substance
Antimetabolite 1 substance
RAF/BRAF inhibitor 1 substance
Checkpoint inhibitor (CTLA-4) 1 substance
Phase III: 6 Phase II: 5 Phase I: 3 Phase I (Other): 1 Phase I (First in Human): 1 Other: 1

Filter these 17 trials by country, sponsor, date range and more.

Open in Search → Gap analysis →
Show: 17 trials

Phase III

6 trials
  • Bristol Myers Squibb International Corporation Commercial
    NIVOLUMAB; NIVOLUMAB, RELATLIMAB
    2023-507688-20-00 13 countries 2021 n=601
    Ended
  • H e x a l AG Commercial
    PEMBROLIZUMAB; PEMETREXED DISODIUM HEMIPENTAHYDRATE
    2024-513160-25-00 3 countries 2024 n=75
    Ended
  • Merck Sharp & Dohme LLC Commercial
    PEMBROLIZUMAB
    2023-509136-25-00 13 countries 2015 n=572
    Ended
  • Pfizer Inc. Commercial
    PEMBROLIZUMAB
    2024-512038-13-00 11 countries 2021 n=161
    Ended
  • Philogen S.p.A. Commercial
    BIFIKAFUSP ALFA; ONFEKAFUSP ALFA
    2024-515749-40-00 4 countries 2016 n=256
    Ended
  • Karolinska University Hospital Academic
    IPILIMUMAB; NIVOLUMAB
    2024-519593-39-00 1 country 2025 n=128
    Recruiting

Phase II

5 trials
  • BioNTech SE Commercial
    CEMIPLIMAB; GINDAMERAN, VIBOSAMERAN, ENOMIMERAN, ONTASAMERAN
    2023-509513-36-00 4 countries 2021 n=157
    Ended
  • Genentech Inc. Commercial
    AUTOGENE CEVUMERAN; PEMBROLIZUMAB
    2023-507389-15-00 2 countries 2020 n=60
    Ended
  • Pfizer Inc. Commercial
    IMP not specified
    2023-509471-17-00 5 countries 2023 n=119
    Ended
  • Oslo University Hospital HF Academic
    RUXOTEMITIDE
    2023-508649-42-00 1 country 2024 n=27
    Recruiting
  • UZ Brussel Academic
    REGORAFENIB
    2024-514087-11-02 1 country 2022 n=87
    Recruiting

Phase I

3 trials
  • Herlev Hospital Academic
    IMP not specified
    2023-509665-20-00 1 country 2024 n=10
    Recruiting
  • Herlev Hospital Academic
    IMP not specified
    2023-510417-25-00 1 country n=10
    Not authorised
  • Herlev Hospital Academic
    IMP not specified
    2023-510417-25-01 1 country 2024 n=10
    Recruiting

Phase I (Other)

1 trial
  • H e x a l AG Commercial
    IMP not specified
    2023-506881-30-00 6 countries 2024 n=136
    Ended

Phase I (First in Human)

1 trial
  • Achilles Therapeutics UK Limited Commercial
    ATL001; NIVOLUMAB
    2024-513062-19-00 1 country 2022 n=8
    Ended

Other

1 trial
  • Amgen Inc. Commercial
    IMP not specified
    2022-502620-49-00 8 countries 2023 n=156
    Ended
Sponsor activity
SponsorTypeTrialsPhasesRecruiting
Herlev Hospital Academic 3 Phase I 2
H e x a l AG Commercial 2 Phase I (Other), Phase III 0
Pfizer Inc. Commercial 2 Phase II, Phase III 0
Amgen Inc. Commercial 1 Other 0
BioNTech SE Commercial 1 Phase II 0
Genentech Inc. Commercial 1 Phase II 0
Bristol Myers Squibb International Corporation Commercial 1 Phase III 0
Merck Sharp & Dohme LLC Commercial 1 Phase III 0
Philogen S.p.A. Commercial 1 Phase III 0
Achilles Therapeutics UK Limited Commercial 1 Phase I (First in Human) 0
Oslo University Hospital HF Academic 1 Phase II 1
UZ Brussel Academic 1 Phase II 1
Karolinska University Hospital Academic 1 Phase III 1
New trials by year
2020
1
2021
3
2022
2
2023
2
2024
5
2025
1
← All indication landscapes